Quick Answer
ALTERITY THERAPEUTICS LTD reported R&D Expense of $14.40 million for fiscal year 2025.
ALTERITY THERAPEUTICS LTD R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $14.40M | -22.7% |
| 2024 | $18.64M | +41.3% |
| 2023 | $13.20M | -10.5% |
| 2022 | $14.75M | +20.0% |
| 2021 | $12.28M | +21.6% |
| 2020 | $10.10M | -22.2% |
| 2019 | $12.98M | +93.8% |
| 2018 | $6.70M | +17.5% |
| 2017 | $5.70M | -40.5% |
| 2016 | $9.59M | — |
- ALTERITY THERAPEUTICS LTD showed a decrease of -22.7% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, ALTERITY THERAPEUTICS LTD’s r&d expense has grown by 50.3% (from $9.59 million to $14.40 million).
- The most recent figure is from ALTERITY THERAPEUTICS LTD’s fiscal year 2025 report (Form 20-F), filed with the SEC on August 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: